 |
|
Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea
Guk-Hee Suh, Sang Keol Lee
Psychiatry Investig. 2009;6(3):185-193. Published online 2009 Jun 23 DOI: https://doi.org/10.4306/pi.2009.6.3.185
|
|
Prospects of the Use of Levetiracetam with Controlled Release of Active Substance: a New Form of Levipil XR in Clinical Practice
Г.И. Наумова
Неврология и нейрохирургия. Восточная Европа.2021; (2): 268. CrossRef Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy
Melissa H. Roberts, Mikiko Y. Takeda, Shannon Kindilien, Yazan K. Barqawi, Matthew E. Borrego
Expert Review of Pharmacoeconomics & Outcomes Research.2018; 18(5): 487. CrossRef A systematic review of economic evaluations of treatments for patients with epilepsy
Ben F.M. Wijnen, Ghislaine A.P.G. van Mastrigt, Silvia M.A.A. Evers, Olga Gershuni, Danielle A.J.E. Lambrechts, Marian H.J.M. Majoie, Debby Postulart, Bert A.P. Aldenkamp, Reina J.A. de Kinderen
Epilepsia.2017; 58(5): 706. CrossRef Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex
Aria Fallah, Alexander G. Weil, Shelly Wang, Evan Lewis, Christine B. Baca, Gary W. Mathern
Epilepsy & Behavior.2016; 63: 79. CrossRef Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy
Reina JA de Kinderen, Debby Postulart, Albert P Aldenkamp, Silvia MAA Evers, Danielle AJE Lambrechts, Anton JA de Louw, Marian HJM Majoie, Janneke PC Grutters
Epilepsy Research.2015; 110: 119. CrossRef The Cost Effectiveness of Newer Epilepsy Treatments
Kristian Bolin, Lars Forsgren
PharmacoEconomics.2012; 30(10): 903. CrossRef
|